跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ETA antagonist
首页
药物
ETA antagonist
ETA antagonist
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Medical application of endothelin A (ETA) receptor antagonist
申请人: SHENZHEN SALUBRIS PHARM CO LTD
优先权: 2024
CN
Pharmaceutical composition of endothelin A (ETA) receptor antagonist compound and application
申请人: SHENZHEN SALUBRIS PHARM CO LTD
优先权: 2023
CN
ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
申请人: SHENZHEN SALUBRIS PHARM CO LTD
优先权: 2021
CN
WO
3 件公开
MEDICAL USE OF COMBINATION OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST AND SGLT-2 INHIBITOR
申请人: SHENZHEN SALUBRIS PHARM CO LTD
优先权: 2024
WO
SALT OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
申请人: SHENZHEN SALUBRIS PHARM CO LTD
优先权: 2022
CN
EP
US
WO
4 件公开
THERAPY FOR COMPLICATIONS OF DIABETES
申请人: GILEAD COLORADO INC
优先权: 2008
US
7 件公开
METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES BY INHIBITING ENDOTHELIN RECEPTORS
申请人: UNIV TEXAS
优先权: 2013
US
Endothelin A receptor antagonist compound, preparation method and medical application thereof
申请人: SHANDONG QUANZHONG BIOMEDICAL TECH CO LTD
优先权: 2024
CN
药物
反馈